share_log

Aditxt | 8-K: Current report

Aditxt | 8-K: Current report

Aditxt | 8-K:重大事件
美股SEC公告 ·  2024/11/20 05:16

Moomoo AI 已提取核心訊息

Aditxt has announced the fourth amendment to its Amended and Restated Merger Agreement with Evofem Biosciences, extending the End Date from November 29, 2024, to January 31, 2025. The merger will result in Evofem becoming a wholly-owned subsidiary of Aditxt.The agreement includes a series of parent equity investments, with Aditxt committing to purchase Evofem's Series F-1 Preferred Stock in multiple tranches. The most recent modification in October 2024 adjusted the Third Parent Equity Investment to $720,000 and increased the Fourth Parent Equity Investment to $2.28 million.The merger agreement, initially signed in December 2023, has undergone several amendments regarding investment timing and amounts. The latest amendment maintains all other terms and conditions of the Amended and Restated Merger Agreement unchanged.
Aditxt has announced the fourth amendment to its Amended and Restated Merger Agreement with Evofem Biosciences, extending the End Date from November 29, 2024, to January 31, 2025. The merger will result in Evofem becoming a wholly-owned subsidiary of Aditxt.The agreement includes a series of parent equity investments, with Aditxt committing to purchase Evofem's Series F-1 Preferred Stock in multiple tranches. The most recent modification in October 2024 adjusted the Third Parent Equity Investment to $720,000 and increased the Fourth Parent Equity Investment to $2.28 million.The merger agreement, initially signed in December 2023, has undergone several amendments regarding investment timing and amounts. The latest amendment maintains all other terms and conditions of the Amended and Restated Merger Agreement unchanged.
Aditxt宣佈對其與Evofem Biosciences的修訂合併協議進行第四次修訂,將結束日期從2024年11月29日延長至2025年1月31日。此次合併將導致Evofem成爲Aditxt的全資子公司。該協議包括一系列母公司股權投資,Aditxt承諾分多個批次購買Evofem的F-1系列優先股票。最新的修改是在2024年10月,將第三次母公司股權投資調整爲720,000美元,並將第四次母公司股權投資增加至228萬。最初於2023年12月簽署的合併協議已經歷多次修改,涉及投資時間和金額。最新的修訂保持了修訂和重述的合併協議的所有其他條款和條件不變。
Aditxt宣佈對其與Evofem Biosciences的修訂合併協議進行第四次修訂,將結束日期從2024年11月29日延長至2025年1月31日。此次合併將導致Evofem成爲Aditxt的全資子公司。該協議包括一系列母公司股權投資,Aditxt承諾分多個批次購買Evofem的F-1系列優先股票。最新的修改是在2024年10月,將第三次母公司股權投資調整爲720,000美元,並將第四次母公司股權投資增加至228萬。最初於2023年12月簽署的合併協議已經歷多次修改,涉及投資時間和金額。最新的修訂保持了修訂和重述的合併協議的所有其他條款和條件不變。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息